ZORTRESS
Total Payments
$8.8M
Transactions
666
Doctors
198
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $291,801 | 2 | 0 |
| 2023 | $715,015 | 4 | 0 |
| 2021 | $1.8M | 5 | 0 |
| 2020 | $667,634 | 9 | 1 |
| 2019 | $439,760 | 60 | 19 |
| 2018 | $1.8M | 232 | 108 |
| 2017 | $3.1M | 354 | 142 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.7M | 161 | 98.5% |
| Space rental or facility fees (teaching hospital only) | $86,500 | 44 | 1.0% |
| Food and Beverage | $31,159 | 413 | 0.4% |
| Consulting Fee | $7,860 | 3 | 0.1% |
| Travel and Lodging | $4,693 | 42 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,120 | 1 | 0.0% |
| Education | $14.18 | 2 | 0.0% |
Payments by Type
Research
$8.7M
161 transactions
General
$134,346
505 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 24 MONTH MULTICENTER RANDOMIZED OPEN LABEL SAFETY AND EFFICACY STUDY OF CONCENTRATION CONTROLLED EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR VS MYCOPHENOLATE WITH STANDARD CALCINEURIN INHIBITOR IN DE NOVO RENAL TRANSPLANTATION | Novartis Pharmaceuticals Corporation | $1.8M | 0 |
| PROPOSED PILOT OF CALCINEURIN INHIBITOR ELIMINATION TRIAL COMPARING RANDOMIZATION AT 3 MONTHS TO CONTINUED PROGRAF AND OR MYFORTIC VS EVEROLIMUS AND OR MYFORTIC REPLACEMTN OF PROGRAF AND OR MYFORTIC FOLLOWING CAMPATH INDUCTION AND STEROID AVOIDANCE | Novartis Pharmaceuticals Corporation | $1.7M | 0 |
| A SINGLE CENTER, OPEN LABEL, RANDOMIZED, PROSPECTIVE, PHASE 4 STUDY OF INDUCTION AND MAINTENANCE IMMUNOSUPPRESSION IN ADULT SUBJECTS AGE >18 UNDER GOING OLT WITH BASILIXIMAB, DELAYED DOSE TACROLIMUS PLUS MYCOPHENOLATE MOFETIL AND STANDARD OF CARE CORTICOSTEROIDS (GROUP 1) VERSUS BASILIXIMAB, DELAYED DOSE TACROLIMUS PLUS MYCOPHENOLATE MOFETIL, SOC CORTICOSTEROIDS WITH ADDITION OF DELAYED MAINTENANCE EVEROLIMUS AT ONE MONTH POST OLT WITH SUBSEQUENT MYCOPHENOLATE MOFETIL MINIMIZATION (GROUP 2) VERS | Novartis Pharmaceuticals Corporation | $1.3M | 0 |
| A single center, open label, randomized, prospective, phase 4 study of induction and maintenance immunosuppression in adult subjects age >18 under going OLT with basiliximab, delayed dose tacrolimus plus mycophenolate mofetil and standard of care corticosteroids (Group 1) versus basiliximab, delayed dose tacrolimus plus mycophenolate mofetil, SOC corticosteroids with addition of delayed maintenance everolimus at one month post OLT with subsequent mycophenolate mofetil minimization (Group 2) | Novartis Pharmaceuticals Corporation | $875,347 | 0 |
| LIVER TRANSPLANT PATIENTS | Novartis Pharmaceuticals Corporation | $416,047 | 0 |
| A RANDOMIZED PROPSEPECTIVE TRIAL OF CONVERSION TO EVEROLIMUS MONOTHERAPY IN MAINTENANCE LIVER TRANSPLANTATION EXAMINATION OF IMPACT ON LONG TERM RENAL FUNCTION | Novartis Pharmaceuticals Corporation | $384,806 | 0 |
| TOLERANCE INDUCTION USING AUTOLOGOUS REGULATORY T CELL INFUSION AND ZORTRESS EVEROLIMUS IN RENAL TRANSPLANT RECIPIENTS A PILOT STUDY | Novartis Pharmaceuticals Corporation | $279,612 | 0 |
| IMPACT OF TWO PRED FREE MAINTENANCE IMMUNOSUPPRESSIVE REGIMENS WITH REDUCED DOSE FK506 PLUSEVEROLIMUS VS STANDARD DOSE FK506 PLUSMMF ON SUBPOPULATION OF T CELLS AND B CELLS PROPSECTIVE SINGLE CENTER STUDY IN RECIPIENTS OF RENAL TRANSPLANT PATIENTS | Novartis Pharmaceuticals Corporation | $254,819 | 0 |
| A SINGLE CENTER, OPEN LABEL, RANDOMIZED, PROSPECTIVE, PHASE 4 STUDY OF INDUCTION AND MAINTENANCE IMMUNOSUPPRESSION IN ADULT SUBJECTS AGE >18 UNDER GOING OLT WITH BASILIXIMAB, DELAYED DOSE TACROLIMUS PLUS MYCOPHENOLATE MOFETIL AND STANDARD OF CARE CORTI | Novartis Pharmaceuticals Corporation | $240,388 | 0 |
| A 60 MONTH MULTI CENTER OPEN LABEL RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVEROLIMUS IMMUNOSUPPRESSION TREATMENT IN LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA EXCEEDING MILAN CRITERIA | Novartis Pharmaceuticals Corporation | $218,789 | 0 |
| A PROSPECTIVE RANDOMIZED SINGLE CENTER PILOT STUDY COMPARING PATIENT AND GRAFT SURVIVAL ADVERSE EVENTS AND TOLERABILITY OF ZORTRESS EVEROLIMUS VERSUS RAPAMUNE SIROLIMUS IN COMBINATION WITH LOW DOSE NEORAL CYCLOSPORINE DOSED BY C2 MONITORING IN DECEASED AND LIVING DONOR RENAL TRANSPLANT RECIPIENTS UNDER A THYMOGLOBULIN ANTITHYMOCYTE GLOBULIN AND RAPID STEROID INDUCTION PROTOCOL | Novartis Pharmaceuticals Corporation | $190,467 | 0 |
| ALTERATIONS IN COGNITIVE FUNCTION AND CEREBRAL BLOOD FLOW AFTER CONVERSION FROM CALCINEURIN INHIBITORS TO EVEROLIMUS | Novartis Pharmaceuticals Corporation | $180,240 | 0 |
| PHARMACOKINETIC ANALYSIS OF ONCE-DAILY ZORTRESS (EVEROLIMUS) AND EXTENDED-RELEASE TACROLIMUS IN RENTAL TRANSPLANT RECIPIENTS | Novartis Pharmaceuticals Corporation | $150,225 | 0 |
| Tolerance Induction Using Autologous Regulatory T cell Infusion and Zortress Everolimus in Renal Transplant Recipients a Pilot Study | Novartis Pharmaceuticals Corporation | $131,470 | 0 |
| A 12 MONTH MULTICENTER OPEN LABEL RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY TOLERABILITY AND SAFETY OF EARLY INTRODUCTION OF EVEROLIMUS REDUCED CNI AND EARLY STEROID ELIMINATION COMPARED TO STANDARD CNI MYCOPHENOLATE MOFETIL AND STEROID REGIMEN IN PAEDIATRIC RENAL TRANSPLANT RECIPIENTS WITH A 24 MONTH ADDITIONAL SAFETY FOLLOW UP | Novartis Pharmaceuticals Corporation | $109,586 | 0 |
| A 24 MONTH RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CONCENTRATION CONTROLLED EVEROLIMUS PLUS REDUCED TACROLIMUS COMPARED TO STANDARD TACROLIMUS IN RECIPIENTS OF LIVING DONOR LIVER TRANSPLANTS | Novartis Pharmaceuticals Corporation | $89,747 | 0 |
| CONVERSION FROM MPA TO ZORTRESS EVEROLIMUS FOR GI TOXICITY POST RENAL TRANSPLANTATION | Novartis Pharmaceuticals Corporation | $68,735 | 0 |
| A PROSPECTIVE RANDOMIZED SINGLE CENTER PILOT STUDY COMPARING PATIENT AND GRAFT SURVIVAL ADVERSE EVENTS AND TOLERABILITY OF ZORTRESS EVEROLIMUS VERSUS RAPAMUNE SIROLIMUS IN COMBINATION WITH LOW DOSE NEORAL CYCLOSPORINE DOSED BY C2 MONITORING IN DECEASED AN | Novartis Pharmaceuticals Corporation | $63,489 | 0 |
| A 24 MONTH MULTICENTER RANDOMIZED OPEN LABEL SAFETY AND EFFICACY STUDY OF CONCENTRATION CONTROLLED EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR VS MYCOPHENOLATE WITH STANDARD CALCINEURIN INHIBITOR IN DE NOVO RENAL TRANSPLANTATION | NOVARTIS PHARMACEUTICALS CORPORATION | $53,103 | 0 |
| A PROSPECTIVE PILOT TRIAL TO EVALUATE SAFETY AND TOLERABILITY OF ZORTRESS EVEROLIMUS FOR THE PREVENTION OF BK AND CMV VIREMIA IN HLA SENSITIZED KIDNEY TRANSPLANT RECIPIENTS | Novartis Pharmaceuticals Corporation | $46,962 | 0 |
Top Doctors Receiving Payments for ZORTRESS
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $8.8M | 199 |
| , M.D | Surgery | Louisville, KY | $4,820 | 6 |
| , M.D | Urology | Los Angeles, CA | $3,120 | 1 |
| , M.D | Transplant Surgery | Rochester, MN | $3,120 | 1 |
| , M.D., PHD | Transplant Surgery | Houston, TX | $3,099 | 19 |
| John Fung | Transplant Surgery | Chicago, IL | $2,364 | 2 |
| , M.D | Nephrology | Los Angeles, CA | $2,298 | 12 |
| , MD | Nephrology | Salt Lake City, UT | $2,047 | 10 |
| , M.D | Internal Medicine | San Francisco, CA | $1,653 | 7 |
| Shamkant Mulgaonkar | — | Livingston, NJ | $1,634 | 7 |
| , MD | Transplant Surgery | Columbus, OH | $1,545 | 9 |
| , MD | Gastroenterology | Murray, UT | $1,468 | 16 |
| , MD | Anesthesiology | San Francisco, CA | $725.97 | 8 |
| , MD | Nephrology | Salt Lake City, UT | $698.61 | 7 |
| , M.D | Surgery | Los Angeles, CA | $662.67 | 9 |
| Nicolae Leca | Internal Medicine | Seattle, WA | $651.21 | 6 |
| , M.D | Transplant Surgery | Detroit, MI | $629.23 | 5 |
| , D.O | Nephrology | Boston, MA | $601.89 | 7 |
| , MD | Nephrology | Cleveland, OH | $549.57 | 6 |
| , M.D | Transplant Surgery | Kansas City, KS | $518.43 | 5 |
| , MD | Transplant Surgery | San Francisco, CA | $503.75 | 5 |
| , M.D | Transplant Surgery | Houston, TX | $475.55 | 6 |
| , MD | Nephrology | New Haven, CT | $451.84 | 4 |
| , M.D | Specialist | Durham, NC | $442.06 | 4 |
| , MD | Urology | Cleveland, OH | $411.11 | 4 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $8.8M
- NOVARTIS PHARMACEUTICALS CORPORATION $54,155
- Novartis Pharma AG $7,470
Product Information
- Type Drug
- Total Payments $8.8M
- Total Doctors 198
- Transactions 666
About ZORTRESS
ZORTRESS is a drug associated with $8.8M in payments to 198 healthcare providers, recorded across 666 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2024. In 2024, $291,801 was paid across 2 transactions to 0 doctors.
The most common payment nature for ZORTRESS is "Unspecified" ($8.7M, 98.5% of total).
ZORTRESS is associated with 20 research studies, including "A 24 MONTH MULTICENTER RANDOMIZED OPEN LABEL SAFETY AND EFFICACY STUDY OF CONCENTRATION CONTROLLED EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR VS MYCOPHENOLATE WITH STANDARD CALCINEURIN INHIBITOR IN DE NOVO RENAL TRANSPLANTATION" ($1.8M).